- Details
- Treatment options in metastatic castration-resistant prostate cancer (mCRPC) who have soft-tissue progression after second-generation anti-androgen therapies are limited. Single-agent studies of cabozantinib, a tyrosine kinase inhibitor (TKI) that regulates cell growth, angiogenesis, and immune cell regulation, and the anti-PD-L1 antibody atezolizumab each showed limited efficacy as monotherapy. (...
|
- Details
- Tanya Dorff joins Alicia Morgans discussing recent updates to the NCCN guidelines for systemic therapies in the treatment of M1 prostate cancer. The CARD trial was a multicenter, randomized, open-label study that enrolled men with metastatic castration-resistant prostate cancer (mCRPC) between 2015 and 2018. Patients were eligible if they had evidence of symptomatic progressive disease within 12 m...
|
- Details
- Rucaparib was evaluated as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA gene alteration who had received prior taxane and androgen receptor–directed therapy. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the clinical rationale which led to the exploration of PARP inhibitors in men with advanced prostate can...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Ben Tran, MBBS, FRACP, highlights the interim results from a phase 1 study of AMG160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) presented at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Biographies: Ben Tran, MBB...
|
- Details
- Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss the US Federal Drug Administration (FDA) recent approval of the FoundationOne® Liquid CDx biopsy test that informs precision medicine in mCRPC. This is a companion diagnostic that serves as a predictive biomarker to identify patients who may benefit from targeted therapies including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibito...
|
- Details
- Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...
|
- Details
- Thomas Keane highlights the PROfound Study, Olaparib for Metastatic Castrate Resistant Prostate Cancer , published in the New England Journal of Medicine this year. The study found that in men with metastatic prostate cancer with genetic alterations relating to homologous recombination repair who have shown disease progression while receiving ezalutamide or abiraterone, olaparib was associated wit...
|
- Details
- In conversation with Alicia Morgans, Philip Koo discusses data from a phase II trial that randomized patients to receive radium-223 and sipuleucel-T or sipuleucel-T alone. Dr. Koo explains that patients who received the combination saw a better PSA response, providing evidence for the continued exploration of the combination of radiation and immunotherapy. Biographies: Phillip J. Koo, MD , FACS Di...
|
- Details
- Lead author of the TRITON-2 study, Wassim Abida joins Charles Ryan to talk about the recent approval of rucaparib, the first PARP Inhibitor approved for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. This approval was based on findings from the TRITON-2 study, rucaparib for post-chemotherapy mCRPC patients who have previously received one AR-targe...
|
- Details
- Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...
|
